Maybe you want to talk about that.

Yeah.

Um, I'm just going to jump back to the first thing that you said, though, about, like, what can we carry over? Um, and I think I'm just going to say that I think that lentivirus is great, and it's a technology that we've learned, like, so much from.

We have huge amounts of follow-up.

It's a de-risk strategy.

So whilst I'm as excited as the next person about all the editing platforms that are coming out, I will carry over the, for the lenti work that we've done for ADA and other things.

Yeah, it's a great, it's a great platform to, uh, treat some of these rare diseases.

I will, I will continue with Claire and Don if, if you would like to also add, um, some thoughts as well.

What's a one idea you hope people take away?

Um, I guess hopefully what this, uh, conference has also shown is that there's, like, not one size fits all approach to this, um, particularly in the ultra-rare space.

Um, so I think, you know, even in that session, we heard, um, Terry Pivarunas talking about, you know, the amazing results that can be achieved with patient-driven research, um, in a very short time and for a very reasonable amount of money.

Yeah

...

the science is amazing, and these are the transformative results that we have, and we can get it to patients.

And I think once we can, like, do that last part, that that will hopefully, you know, stimulate people.

But still, yeah, come and do ...